Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATTERHORN-CN: Durvalumab and FLOT in Chinese Patients With Resectable Gastric and Gastroesophageal Junction Cancer
NCT07877818Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2026
- Primary completion
- Nov 2029
01
Overview
A Phase 3 trial of durvalumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07877818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877818.